Boston Type 1 Keratoprosthesis: Visual Outcomes, Device Retention, and Complications
Overview
Authors
Affiliations
Purpose: To determine the visual outcomes, device retention, and complications after Boston type 1 keratoprosthesis (KPro-1) device implantation.
Methods: Comprehensive review of every case of KPro-1 implantation at a tertiary eye care center.
Results: The initial KPro-1 procedure, performed in 75 eyes without a previous keratoprosthesis, was included in the analysis. During the first 6 postoperative months, improvement occurred in the mean preoperative best-corrected visual acuity of 20/1265 to a mean best-obtained postoperative visual acuity of 20/97 (P < 0.001). After a mean follow-up period of 41.4 months (range, 0.8-82.8 months), the final mean best-corrected visual acuity was 20/428. Improved vision was recorded in 43 eyes (57.3%), ambulatory vision (≥20/400) in 47 eyes (62.7%), intermediate functional vision (≥20/80) in 23 eyes (30.7%), and full functional vision (≥20/40) in 11 eyes (14.7%). The initial device was retained in 64 eyes (85.3%), with a Kaplan-Meier retention probability of 96% at 6 months and 82% at 5 years. One or more sight-threatening complications occurred in 51 eyes (68%). These included device extrusion in 11 eyes (14.7%), ulcerative keratitis in 12 eyes (16%), endophthalmitis in 7 eyes (9.3%), sterile vitritis in 3 eyes (4%), retroprosthetic membranes in 25 eyes (33.3%), maculopathy in 26 eyes (34.7%), retinal detachment in 9 eyes (12%), and progressive optic neuropathy in 7 eyes (9.3%).
Conclusions: Boston KPro-1 implantation is associated with satisfactory visual outcomes and excellent device retention in a majority of cases. However, serious postoperative complications are common and may compromise the final visual result.
Two cases of therapeutic scleral lenses for KID syndrome.
Gagliardi M, Asghari B Am J Ophthalmol Case Rep. 2025; 37:102261.
PMID: 39927073 PMC: 11804770. DOI: 10.1016/j.ajoc.2025.102261.
Antibacterial and cytocompatible silver coating for titanium Boston Keratoprosthesis.
Gomez S, Ginebra M, Gil F, Barraquer R, Manero J Front Bioeng Biotechnol. 2024; 12:1421706.
PMID: 39364264 PMC: 11446748. DOI: 10.3389/fbioe.2024.1421706.
Wu K, Mina M, Carbonneau M, Marchand M, Tran S Micromachines (Basel). 2023; 14(10).
PMID: 37893352 PMC: 10609220. DOI: 10.3390/mi14101915.
Application of biomaterials and nanotechnology in corneal tissue engineering.
Soleimani M, Ebrahimi Z, Ebrahimi K, Farhadian N, Shahlaei M, Cheraqpour K J Int Med Res. 2023; 51(7):3000605231190473.
PMID: 37523589 PMC: 10392709. DOI: 10.1177/03000605231190473.
Metalloproteinase-9 in the ocular surface of patients with implanted Boston type 1 keratoprosthesis.
Arteaga A, Weiss M, Perez R, Cortina M Cornea Open. 2023; 2(1).
PMID: 37092032 PMC: 10121193. DOI: 10.1097/coa.0000000000000008.